Pharmaceuticals

Lionco

Lionco released FY2026 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 86.54 M, actual EPS CNY 0.0041

Lionco released FY2025 Annual Earnings on April 24 After-Market (BJT), Actual Revenue: CNY 322.48 M, Actual EPS: CNY -0.27

Lionco released FY2025 Q4 earnings on April 24 After-Market (BJT), actual revenue CNY 40.62 M, actual EPS CNY -0.2276

Lionco to Release FY2026 Q1 Earnings on April 25 After-Market (BJT)

Lionco to Release FY2025 Earnings Report on April 25 After-Market (BJT)

Lionco released FY2025 9 Months Earnings on October 30 After-Market (BJT), actual revenue CNY 281.86 M, actual EPS CNY -0.0494

Lionco released FY2025 Q3 earnings on October 30 After-Market (BJT), actual revenue CNY 110.25M, actual EPS CNY 0.0016

Lionco FY2025 Q3 Earnings Release on October 31, 2025, After-Market (BJT)

Lionco released FY2025 Q2 earnings on August 22 Pre-Market (BJT), actual revenue CNY 121.49 M, actual EPS CNY -0.0211

Lionco released FY2025 Semi-Annual Earnings on August 22 Pre-Market (BJT), Actual Revenue: CNY 171.61 M, Actual EPS: CNY -0.05

Lionco to Release FY2025 Semi-Annual Earnings on August 23, 2025 (BJT)

Lingkang Pharmaceutical Reports Loss for First Half of 2025

Lingkang Pharmaceutical 2025 Q1 Report: Main Business Revenue Down 34.79%

Lionco released FY2025 Q1 earnings on April 25 After-Market (BJT), actual revenue CNY 50.12 M, actual EPS CNY -0.03

Lionco FY2025 Q1 Earnings Release Scheduled for April 26 After-Market BJT

Lionco released FY2024 annual earnings on April 18 After-Market (BJT), actual revenue CNY 379.78 M, actual EPS CNY -0.1813

Lionco released FY2024 Q4 earnings on April 18 After-Market (BJT), actual revenue CNY 148.75 M, actual EPS CNY -0.0959

Lingkang Pharmaceutical's Meilanshike Drug Passes Consistency Evaluation, Stock Rises 5%

Lingkang Pharmaceutical's Subsidiary Injection Vecuronium Bromide Passes Consistency Evaluation

Lionco FY2024 Annual Earnings Release on April 19, 2025, After-Market BJT

603669

Lionco announced that its wholly-owned subsidiary Lionco Pharmaceutical's injectable cefazolin sodium product is expected to be selected for the national centralized drug procurement, with an estimated sales revenue of 23.0089 million yuan in 2024, accounting for 6.06% of the company's annual operating income. If the contract is successfully signed, it will help expand the market and enhance brand influence, but there is uncertainty regarding the subsequent contract signing. The company will closely monitor the progress and fulfill its information disclosure obligations

Zhitong

Lionco: Subsidiary Lionco Pharmaceutical's product, injectable cefazolin sodium, is expected to be selected for national centralized drug procurement

688202

688621

301363

The A-share CRO concept sector has seen a surge, with Lionco hitting the daily limit, MeHow rising over 10%, and Haoyuan Pharmaceutical, Boji Pharmaceutical, Medicilon, Sun-Novo, and Heyuan Biotechnology also following suit

Medicilon

Sun-Novo

MeHow

300452

The chemical pharmaceutical sector continues to rise, with SUNHERE and Lionco hitting the daily limit, while Beilu Pharmaceutical, Hanyu Pharmaceutical, Yong'an Pharmaceutical, Xinghao Pharmaceutical, and Hasenlian also follow suit

SUNHERE

Beilu Pharma

HYBIO

YONGAN PHARMACEUTICAL

MEDISAN

The chemical pharmaceutical sector continues to rise, with SUNHERE and Lionco hitting the daily limit

301096

688602

603127

06127

002821

06821

CRO concept stocks saw a partial rise, with Lionco hitting the limit up, and Bio-S, Chemspec, JOINN, and Asymchem following suit

Bio-S

Chemspec

JOINN

Asymchem

CRO concept stocks partially rose, Lionco surged to the daily limit

Lionco announced that its wholly-owned subsidiary Hainan Lionco Pharmaceutical Co., Ltd. recently obtained the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration's Drug Evaluation Center for Acetazolamide Sustained-Release Capsules. This drug is suitable for the prevention or improvement of symptoms related to acute mountain sickness that may still occur under gradually rising conditions. Currently, there are no other companies in China applying for this product, and Lionco Pharmaceutical has invested research and development expenses of 6.9 million RMB

Lionco: Wholly-owned subsidiary receives clinical trial approval notice for acetazolamide sustained-release capsule medication

According to the Zhitong Finance APP, Lionco disclosed its first-quarter report for 2025, showing that the company achieved revenue of 50.12 million yuan, a year-on-year decrease of 34.79%; the net profit attributable to the parent company was a loss of 18.62 million yuan; the net profit excluding non-recurring gains and losses was a loss of 17.91 million yuan. The basic earnings per share were -0.03 yuan

Lionco released its first-quarter performance, with a net loss attributable to the parent company of 18.62 million yuan

300267

000953

The chemical pharmaceutical sector has shown strong fluctuations, with HC CHEMICAL and Lionco hitting the daily limit, ER-KANG rising over 10%, and Luoxin Pharmaceutical and Yifang Biotechnology both surging

ER-KANG

HC CHEMICAL

Luoxin Pharmaceutical

InventisBio

The chemical pharmaceutical sector fluctuated and strengthened, with HC CHEMICAL and Lionco hitting the limit-up

According to the Zhitong Finance APP, Lionco disclosed its 2024 annual report, stating that the company achieved revenue of 380 million yuan during the reporting period, a year-on-year increase of 92.95%; the net profit attributable to the parent company was a loss of 131 million yuan, a year-on-year narrowing; the net profit excluding non-recurring gains and losses was a loss of 180 million yuan, also a year-on-year narrowing; basic earnings per share were -0.18 yuan

Lionco released its 2024 annual performance, with a net loss attributable to the parent company of 131 million yuan

Lionco announced that its wholly-owned subsidiary Hainan Meilan Shike Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the injection of Vecuronium Bromide to pass the consistency evaluation of generic drugs. This medication is primarily used as an adjunct to general anesthesia, suitable for tracheal intubation and muscle relaxation during surgery

Lionco: Injectable Vecuronium Bromide has passed the consistency evaluation for generic drugs

Lionco(603669.SH)